ITOS Relative Valuation
ITOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ITOS is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.68
P/B
Median3y
0.79
Median5y
1.46
-25.78
FCF Yield
Median3y
-19.12
Median5y
-5.14
Competitors Valuation Multiple
The average P/S ratio for ITOS's competitors is 19.16, providing a benchmark for relative valuation. Iteos Therapeutics Inc Corp (ITOS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Iteos Therapeutics Inc (ITOS) currently overvalued or undervalued?
What is Iteos Therapeutics Inc (ITOS) fair value?
How does ITOS's valuation metrics compare to the industry average?
What is the current P/B ratio for Iteos Therapeutics Inc (ITOS) as of Jun 16 2025?
What is the current FCF Yield for Iteos Therapeutics Inc (ITOS) as of Jun 16 2025?
What is the current Forward P/E ratio for Iteos Therapeutics Inc (ITOS) as of Jun 16 2025?